New COVID-19 Vaccine Added to UK Autumn Programme for 2026
The UK government has announced a new addition to its national vaccination strategy. Starting in the autumn of 2026, the COVID-19 booster programme will include a new vaccine called Bimverax LP.8.1. This decision follows a partnership between the Spanish pharmaceutical company HIPRA and the UK-based firm Accord Healthcare.
Bimverax is a protein-based vaccine designed to provide protection against the latest variants of the virus. Health officials hope that adding this new option will help maintain high levels of immunity among the population, particularly for those most at risk of becoming seriously ill during the winter months.
This update is part of the UK’s ongoing effort to manage COVID-19 alongside other seasonal illnesses, such as the flu. By including a variety of vaccines in the national programme, the health service aims to offer more flexibility and ensure that the most effective protection is available to patients across the country.
While the vaccine will not be available until the 2026/27 season, the announcement provides clarity for healthcare providers planning their future logistics. The government continues to monitor virus trends to ensure that the national vaccination schedule remains effective in protecting public health.